Delivery Order SPE2DB22D3019-SPE2DB26FK2TV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $9,164.04. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $31,396.02. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,517.05 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. The contract, issued on June 4, 2025, with completion targeted for June 5, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency issued a delivery order valued at $14,994.54 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packages. This firm fixed-price delivery order, awarded on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $3,893.43 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-unit packaging. The contract is a firm fixed-price delivery order with an ultimate completion date of October 31, 2025, and was awarded on October 30, 2025. This award is non-set-aside and competitively awarded, reflecting AmerisourceBergen's capability to meet federal procurement requirements. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $1,860.18. The contract is a firm fixed-price delivery order with an ultimate completion date of July 7, 2025, and was awarded on July 3, 2025 without a set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,645.28 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by May 2, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for 12,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-unit bottles, with a ceiling value of $2,177.21 and an ultimate completion date of November 7, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a small-value transaction under...
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB26FK2TVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,524.22 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. The contract, executed on November 4, 2025, with completion targeted for November 5, 2025, employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and related healthcare commodities to military healthcare systems and other federal government customers. AmerisourceBergen's status as a major pharmaceutical distributor and its demonstrated capacity to fulfill federal medical procurement requirements through open competition make it a critical vendor for supporting military and veteran healthcare supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 11/4/25 |